← Leaderboards
Kunwar Shailubhai
Callisto Pharmaceuticals, Inc.
$2,411,746
Attributed
$2,599,670
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $510.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,599,670 · 7
By mechanism
R43$960,212 · 4
U01$876,831 · 1
R21$762,627 · 2
Top collaborators
- Margie L. Clapper2 shared
Others in their field
Top investigators on “Guanylate Cyclase”
- Alexander M Dizhoor · Wayne State University$9,811,543
- Annie V Beuve · Univ Of Med/Dent Of Nj-Nj Medical School$7,886,918
- Dennis J Stuehr · Cleveland Clinic Foundation$7,697,286
- Wolfgang Baehr · University Of Utah$7,221,171
- Rakesh C. Kukreja · University Of Central Florida$7,211,000
- James B Ames · University Of Md Biotechnology Institute$6,882,505
Research focus
Guanylate CyclaseColonic PolypsAnalogColitisUroguanylinColorectal CancerCyclic GmpProductionPolypsEpithelial CellsAgonistTissuesGuanylinInflammationNovel StrategiesColon CarcinomaAdenocarcinomaCell LinePharmaceutical PreparationsMucous MembraneInflammatoryOral AdministrationInflammatory Bowel DiseasesColon Carcinogenesis
Grant awards (11)
Combination of formulated dolcanatide, a guanylate cyclase-C agonist, with formulated atiprimod, a JAK-STAT inhibitor, for treatment of murine colitis.$358,039
R43 · FY2025 · DK · contact PI
Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis$90,723
R43 · FY2025 · CA · contact PI
Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis$308,650
R43 · FY2024 · CA · contact PI
GC-C Agonists: Specific Probes for the Detection of Colorectal Tumors$199,269
R21 · FY2013 · CA · contact PI
GC-C Agonists: Specific Probes for the Detection of Colorectal Tumors$176,579
R21 · FY2012 · CA · contact PI
GC-C agonists for colitis-induced CRC$184,767
R21 · FY2009 · CA · contact PI
GC-C agonists for colitis-induced CRC$202,012
R21 · FY2008 · CA · contact PI
Peptide & antibodies as antidotes for superantigens$366,211
U01 · FY2006 · AI · contact PI
Peptide &antibodies as antidotes for superantigens$510,620
U01 · FY2005 · AI
Agonists of guanylate cyclase receptor for colon cancer$104,800
R43 · FY2002 · CA
Cloning, expression and purification of uroguanylin$98,000
R43 · FY2002 · CA